1-Methyl-2-cyclopentylpyrrol | 60444-02-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-Methyl-2-cyclopentylpyrrol
• 英文别名: 2-Cyclopentyl-1-methylpyrrole
• CAS: 60444-02-2
• 化学式: C₁₀H₁₅N
• 分子量: 149.236
• InChiKey: URSHZUDETJACPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  (E)-4-chloro-1-cyclopentylbut-2-en-1-one 、 甲胺 生成 1-Methyl-2-cyclopentylpyrrol
  参考文献：
  名称：

  BAJRAMOV, G. M.;GODZHAEV, S. P.;GOYUSHOV, R. D., AZERB. XIM. ZH., 1985, N 2, 79-82

  摘要：

  DOI：

文献信息

• Histone demethylase inhibitors
  申请人：CELGENE QUANTICEL RESEARCH, INC.

  公开号：US10174026B2

  公开（公告）日：2019-01-08

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明一般涉及治疗癌症和肿瘤性疾病的组合物和方法。本发明提供了取代的吡咯并吡啶衍生物化合物和包含所述化合物的药物组合物。所述化合物和组合物可用于抑制组蛋白去甲基化酶。此外，所述化合物和组合物还可用于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。
• SOTOYAMA T.; HARA S.; SUZUKI A., BULL. CHEM. SOC. JAP., 1979, 52, NO 6, 1865-1866
  作者：SOTOYAMA T.、 HARA S.、 SUZUKI A.

  DOI：——

  日期：——
• MARINELLI E. R.; LEVY A.B., TETRAHEDRON LETT.,1979, NO 25, 2313-2316
  作者：MARINELLI E. R.、 LEVY A.B.

  DOI：——

  日期：——
• IBRAGIMOV I. I.; KOST A. N.; GUSEJNOV M. M.; GADZHILY R. A.; GODZHAEV S. +, XIMIYA GETEROTSIKL. SOEDIN. <KGSS-AQ>, 1976, HO 6, 790-793
  作者：IBRAGIMOV I. I.、 KOST A. N.、 GUSEJNOV M. M.、 GADZHILY R. A.、 GODZHAEV S. +

  DOI：——

  日期：——
• HISTONE DEMETHYLASE INHIBITORS
  申请人：CELGENE QUANTICEL RESEARCH, INC.

  公开号：US20170313702A1

  公开（公告）日：2017-11-02

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.